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ASXL2 is an ETP family protein that interacts with
PPARg. We find that ASXL2/ mice are insulin
resistant, lipodystrophic, and fail to respond to a
high-fat diet. Consistent with genetic variation at
the ASXL2 locus and human bone mineral density,
ASXL2/ mice are also severely osteopetrotic
because of failed osteoclast differentiation attended
by normal bone formation. ASXL2 regulates the oste-
oclast via two distinct signaling pathways. It induces
osteoclast formation in a PPARg/c-Fos-dependent
manner and is required for RANK ligand- and thiazo-
lidinedione-induced bone resorption independent of
PGC-1b. ASXL2 also promotes osteoclast mitochon-
drial biogenesis in a process mediated by PGC-1b
but independent of c-Fos. Thus, ASXL2 is a master
regulator of skeletal, lipid, and glucose homeostasis.INTRODUCTION
The incidence of insulin-resistant diabetes mellitus is probably
the most rapidly increasing of any endemic disease in the United
States. Obesity promotes type 2 diabetes (T2-DM), but not all
obese individuals have diabetes, suggesting that the influence
of genetic factors, particularly in specific ethnic groups, is sub-
stantial. T2-DM has skeletal complications. Diabetic patients
are predisposed to fractures that heal poorly, in part because
of compromised osteoclast function (de Liefde et al., 2005;
Hernandez et al., 2012; Janghorbani et al., 2007; Kasahara
et al., 2010; Vestergaard, 2007). Osteoclasts also probably
contribute to the increased fracture incidence reported with thia-
zolidinedione (TZD) therapy (Kasahara et al., 2010; Lazarenko
et al., 2007; Li et al., 2006; Sottile et al., 2004; Wan et al.,
2007). Furthermore, recent evidence indicates the skeletonCepromotes glucose homeostasis via the osteoblast-specific pro-
tein, osteocalcin (Lee et al., 2007). The osteoclast is proposed
to participate in this process by de-carboxylating osteocalcin
and thus enabling it to stimulate pancreatic b cells to produce
insulin (Ferron et al., 2010).
We recently utilized genome-wide screening to identify bone
mineral density (BMD)-associated genes in mice (Farber et al.,
2011) and found that the most-significant BMD SNPs were in the
ASXL2 gene. Establishing clinical relevance, SNPs within ASXL2
are associated with human BMD in two cohorts (Ghazalpour
et al., 2012; Nielson et al., 2010).
ASXL2 is a mammalian homolog of the Drosophila gene, ASX,
which encodes an ETP protein, regulating histone methylation
(Baskind et al., 2009). To gain insight into the means by which
ASXL2 impacts the skeleton, we performed gene cluster analysis
(Farber et al., 2011). Because we found the genes most promi-
nently co-expressed with ASXL2 are those mediating myeloid
differentiation, we postulated ASXL2 likely impacts the osteo-
clast, a member of the monocyte/macrophage family. In the pre-
sent study, we find ASXL2/ osteoclastogenesis is attenuated
in vitro and in vivo. In keeping with a paucity of bone-resorptive
cells, trabecular bonemass is increasedmore than 400% inmice
lacking ASXL2.
PPARg is a nuclear receptor that, in its unliganded state, is inac-
tive due to association with co-repressing molecules (Tontonoz
and Spiegelman, 2008). Upon ligand-induced activation, co-
repressors disassociate and PPARg recruits co-factors that
enable transactivation of target genes. This nuclear receptor reg-
ulates insulin sensitivity and adipogenesis and can be involved in
the pathogenesis of T2-DM. The preponderance of evidence indi-
cates that fat is the primary tissue targeted by PPARg to enhance
insulin sensitivitywhere it promotesstorageofdietary fatty acids in
adipose tissues. TZDs, pharmacological activators of PPARg,
exert their insulin-sensitizingeffectsprimarily by lowering free fatty
acids.
TZDs, such as rosiglitazone (ROSI) have, until recently,
enjoyed wide use in treating insulin resistance. Administrationll Reports 11, 1625–1637, June 16, 2015 ª2015 The Authors 1625
of these drugs is, however, restricted because of complications,
including predisposition to fracture (Grey, 2009). Thus, the
means by which activated PPARg compromises the skeleton
has important clinical implications.
PPARg exerts its skeletal effects by impacting both osteo-
blasts and osteoclasts. In the case of osteoblasts, the nuclear
receptor commits common precursor mesenchymal stem cells
to differentiate into adipocytes at the cost of osteoblastogenesis,
thereby reducing bone formation. PPARg promotes osteoclast
differentiation via activation of the osteoclastogenic AP-1 tran-
scription factor, c-Fos (Wan et al., 2007). Thus, a reasonable
hypothesis holds that TZD-mediated bone loss represents sup-
pressed formation and enhanced resorption. In fact, enhanced
resorption is the exclusive cause of ROSI-induced bone loss in
mice (Fukunaga et al., 2015) and a component of the increased
fracture risk in women (Zinman et al., 2010).
ASXL2 interacts with PPARg and activates adipogenic genes
(Park et al., 2011), raising the possibility ASXL2 may participate
in the bone-regulating effects of the nuclear receptor. We find
thatASXL2 is necessary for cell-autonomousosteoclastogenesis
in a PPARg/c-Fos-dependent manner. Thus, ASXL2 deficiency
obviates the osteoclast-inducing capacity of ROSI. ASXL2 also
promotes mitochondrial biogenesis in osteoclasts via PGC1-b
in amanner independent of differentiation and c-Fos expression.
Attesting to its cell specificity, ASXL2 does not regulate osteo-
blastic bone formation. Furthermore, ASXL2-deficient mice
are lipodystrophic and relatively unresponsive to high-fat diet
(HFD). They have impaired glucose homeostasis, and liver, fat,
muscle, and osteoclast precursors are insulin resistant. Thus,
ASXL2 regulates skeletal, glucose, and adipocyte homeostasis.
RESULTS
ASXL2 Deficiency Inhibits Osteoclastogenesis
With the discovery that ASXL2 SNPs are associated with murine
BMD, we knocked ASXL2 down in osteoclast precursors in the
form of bone marrow macrophages (BMMs) and discovered a
marked arrest of osteoclastogenesis (Farber et al., 2011). To
determine the physiological relevance of this observation, we
cultured BMMs of ASXL2/ mice in M-CSF and increasing
amounts of the osteoclast-differentiating cytokine, RANK ligand
(RANKL). ASXL2-deficient osteoclast number is substantially
reduced at all RANKL concentrations (Figures 1A andS1A). Simi-
larly, temporal expression of osteoclast differentiation markers
is arrested in RANKL + M-CSF-exposed ASXL2/ BMMs
(Figures 1B and S1B). Reflecting reduced numbers of the
bone-resorptive cells, mobilization of CTx, a product of collagen
degradation, is diminished in cultures of ASXL2/ osteo-
clasts generated on bone (Figure 1C). Osteoclastogenesis of
ASXL2+/ BMMs mirrors WT (not shown).
The fact that osteoclastogenesis of ASXL2/ BMMs is
dampened, in the absence of stromal cells or osteoblasts, sug-
gests the influence of a mechanism endogenous to the osteo-
clast precursor (osteoclast autonomous). To determine whether
such is the case, we transduced ASXL2/ BMMs with ASXL2
or empty vector. Likely because of construct size, transduction
efficiency is less than optimal, resulting in ASXL2 expression
approximately 1/3 that of WT cells (Figure S1C). Despite this lim-1626 Cell Reports 11, 1625–1637, June 16, 2015 ª2015 The Authorsitation, ASXL2 substantially, although incompletely, rescues
osteoclast formation by mutant BMMs, establishing a cell-
autonomous influence (Figure 1D). In keeping with the partial
rescue of the mutant cells by the WT construct, expression of
the osteoclastogenic transcription factors, c-Fos and NFATc1
are significantly but modestly increased (Figure S1C). Because
the partial rescue of ASXL2/ osteoclastogenesis by ASXL2
transduction raised the possibility of a non-cell-autonomous
influence, we generated various co-cultures of mutant and WT
BMMs and osteoblasts in osteoclastogenic conditions. These
experiments were based upon the fact that cytokines produced
by osteoblast lineage cells are the key inducers of osteoclast
differentiation. Consistent with diminished RANKL expression
(Figure S1D), ASXL2/ osteoblasts exert a modest negative
influence on commitment of WT BMMs to the osteoclast
phenotype (Figure 1E). Osteoclastogenesis, however, is virtually
arrested when mutant BMMs are cultured with either WT or
ASXL2-deficient osteoblasts. Thus, whereas RANKL production
by ASXL2/ osteoblast lineage cells is dampened, the defi-
ciency does not contribute to the diminished number of mutant
osteoclasts.
Exposure of BMMs to mesenchymal cell-produced RANKL,
in vivo, primes them to differentiate into osteoclasts, ex vivo
(Lam et al., 2000). To determine whether ASXL2/ osteoclast
precursors respond to such priming, we transplanted WT or
ASXL2/ marrow in irradiated WT mice, a model in which all
derivative osteoclasts, but not osteoblasts, are of donor origin
(Lam et al., 2000). Marrow was obtained from the transplanted
animals after 6 weeks and BMMs cultured in RANKL + M-CSF.
BMMs of WT > WT chimeras generate abundant osteoclasts,
which are virtually absent when the cultured cells are obtained
from marrow of ASXL2/ > WT chimeras (Figure 1F). Thus, in
keeping with the cell-autonomous nature of the process,
ASXL2/ osteoclast precursors are resistant to priming by
differentiation-inducing cytokines, in vivo.
ASXL2/ Mice Are Osteopetrotic
These observations establish that ASXL2 deficiency compro-
mises osteoclast formation in a cell-autonomous manner.
Because osteopetrosis represents increased bone mass due
to compromised osteoclast formation and/or function, we
measured bone mass of mutant mice by mCT. In fact, femoral
trabecular bone mass (BV/TV) is increased approximately
400% in ASXL2/ mice (Figure 1G). Trabecular connectivity,
spacing, and number exhibit equally impressive changes (Fig-
ure S1E). Histomorphometric analysis reveals the same abun-
dance of trabecular bone mass, and in keeping with our in vitro
data, a significant decrease in osteoclast number (Figure 1H).
Interestingly, whereas vertebral BV/TV is increased in absence
of ASXL2, the change is relatively modest compared to appen-
dicular bone (Figure S1F). Similar to other osteopetrotic animals,
cortical thickness is reduced, eventuating in compromised bone
strength (Figure S1G) (Li et al., 1999). As in human glucose intol-
erance (vide infra), fracture healing of ASXL2/ mice is also
retarded (Figure S1H).
Osteopetrosis is often associated with splenomegaly due to
extramedullary hematopoiesis, and ASXL2/ mice have
enlarged spleens (p < 0.01). An abundance of megakaryocytes
Figure 1. ASXL2 Deficiency Results in Impaired Osteoclastogenesis
(A) WT and ASXL2/ BMMs were cultured with M-CSF and RANKL for 5 days, and osteoclasts were counted.
(B) Osteoclast differentiation proteins were determined by immunoblot, with time.
(C) BMMs were cultured on bone with M-CSF and RANKL and medium CTx determined.
(D) ASXL2/ BMMs, transduced with ASXL2 or vector, were exposed to M-CSF and RANKL for 5 days. The cells were TRAP stained. Vector-transduced WT
cells serve as control.
(E) Various combinations of WT and ASXL2/ BMMs and calvarial osteoblasts were co-cultured, and osteoclasts were counted.
(F) WT or ASXL2/ marrow were transplanted into irradiated WT hosts. Osteoclasts were generated from BMMs, ex vivo, 6 weeks after transplantation.
(G) Femurs of 13-week-old ASXL2/ and WT littermates were subjected to mCT analysis and trabecular bone volume (BV/TV) determined.
(H) Static and dynamic histomorphometric determination of trabecular bone of ASXL2/ and WT mice.
(I) Weight and body length of WT and ASXL2/ mice. The scale bar represents 400 mm.
Data are expressed as mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001.
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(not shown), taken with a paucity of bone marrow cells, estab-
lishes the splenomegaly of the mutant mice reflects extramedul-
lary hematopoiesis (Figure S1I).
These data stand in contradistinction to our report of
decreased BMD, as determined by DXA, in ASXL2/ mice
(Farber et al., 2011). DXA analysis is, however, modified by sub-
ject size, and the results decrease in face of smaller bone, thus
obviating meaningful interpretation in pediatric patients (Reid,
2010). In this regard, ASXL2/ mice are smaller and weigh
less than their WT counterparts (Figure 1I). The fact that the pro-
jected bone area of ASXL2/ femurs is reduced approximately
1/3 (WT 0.96 ± 0.03 mm2; ASXL2/ 0.67 ± 0.03 mm2; p < 0.01)
explains the discrepancy between the substantially enhanced
trabecular bone volume determined by mCT and the artifactually
low BMD measured by DXA.
ASXL2 is abundantly expressed in osteoblasts (Farber et al.,
2011). Thus, whereas our data establish ASXL2/ mice are
osteopetrotic, it is possible that, as in other forms of osteopet-
rosis, enhanced osteoblast activity may contribute to the
increased bone mass (Marzia et al., 2000). ASXL2, however,
does not appear to regulate bone formation because temporal
expression of osteocalcin, bone sialoprotein, alkaline phospha-
tase, and collagen 1 mRNA, by ASXL2/ and WT cultured
osteoblasts, is indistinguishable (Figure S1J). The same holds
regarding in vivo osteoblast number and circulating osteocalcin
(Figures 1H and S1K). Moreover, differentiation of marrow stro-
mal cells into bone-forming osteoblasts is unaltered in absence
of ASXL2 (Figure S1L). To kinetically determine the impact of
ASXL2 deletion on osteogenesis, we administered time-spaced
doses of calcein andmeasured parameters of bone formation in
non-decalcified sections. Mineral apposition (MAR) and bone
formation (BFR) rates are the same in ASXL2/ and WT ani-
mals (Figure 1H). Thus, ASXL2 deficiency increases bone
mass by attenuating osteoclast formation without impacting
osteoblasts.
PPARg Mediates ASXL2-Stimulated
Osteoclastogenesis
Activated PPARg promotes osteoclastogenesis, and its
absence, in BMMs, inhibits differentiation into mature bone-
resorbing cells (Wan et al., 2007). Furthermore, conditional dele-
tion of the nuclear receptor in hematopoietic and endothelial
cells increases bone mass (Wan et al., 2007). ASXL2 and PPARg
interact in other cells, raising the possibility the nuclear receptor
may mediate ASXL2’s osteoclastogenic capacity (Park et al.,
2011). To test this hypothesis, we first asked whether the
ASXM2 domain of ASXL2, which is the binding site of PPARg’s
transcriptional partner, RXRa (Katoh, 2013), mediates osteoclast
formation. In contrast to the induction of osteoclast differentia-
tion markers by WT ASXL2, lacking the ASXM2 domain is inca-
pable of doing so in mutant BMMs (Figure S2A; relative mRNA
expression: Vect = 1; WT = 1.9; Delta ASXM2 = 2.4).
We next transfected 293T cells with a PPARg luciferase re-
porter, with or without PPARg (Figure 2A). Co-transfection with
ASXL2 dose dependently increases luciferase activity only in
the presence of PPARg (Figure 2A). Furthermore, ROSI, which
therapeutically stimulates PPARg in diabetic patients, synergis-
tically enhances the capacity of ASXL2 to induce the PPARg1628 Cell Reports 11, 1625–1637, June 16, 2015 ª2015 The Authorsreporter construct. ROSI also substantially increases ASXL2/
PPARg association (Figure 2B). Further supporting its regulation
of the nuclear receptor’s osteoclastogenic effects, induction of
the PPARg target gene, CD36, requires ASXL2 (Figure 2C).
ASXL2 also dampens PPARg SUMOylation, a process which
represses the nuclear receptor’s transcriptional activity (van
Beekum et al., 2009) (Figure 2D). Establishing a central role of
ASXL2 in PPARg-mediated osteoclast formation, induction of
the bone-resorptive polykaryon, by ROSI, is completely arrested
in knockout cells (Figures 2E and S2B). On the other hand, ROSI-
induced osteoclastogenesis does not reflect stimulated expres-
sion of ASXL2 by the TZD (Figure S2C) nor does ASXL2
deficiency affect PPARg expression (Figure S2D). Thus, ASXL2
partners with ROSI to promote osteoclast formation via PPARg
activation.
c-Fos Mediates ASXL2-Induced Osteoclastogenesis
ASXL2 is essential for RANKL-stimulated expression of the AP-1
transcription factor, c-Fos, deficiency of which completely
arrests osteoclastogenesis, thereby promoting severe osteopet-
rosis (Figures 2F and S2E) (Grigoriadis et al., 1994). In keeping
with c-Fos’s essential role as an ASXL2 effector, transduction
of the AP-1 protein rescues the osteoclastogenic capacity of
ASXL2/ BMMs (Figures 2G, 2H, S2F, and S2G). Interestingly,
c-Fos is a PPARg target gene whose expression is enhanced in
osteoclast precursors by ROSI (Wan et al., 2007). In fact, in the
absence of ASXL2, PPARg binding to its c-Fos response
element does not increase with osteoclast differentiation, nor is
it heightened by ROSI (Figure 2I).
RANK-Stimulated Osteoclast Formation Requires
ASXL2
Differentiation of progenitors into mature osteoclasts is princi-
pally, if not exclusively, the purview of RANKL. In this regard,
transduction of the RANKL-induced, essential transcription fac-
tor, NFATc1 substantially rescues the osteoclastogenic capacity
of ASXL2/ BMMs (Figures 3A–3C). Consistent with c-Fos
being upstream of NFATc1 in osteoclastogenesis, transduction
of NFATc1 does not increase c-Fos expression in ASXL2/
osteoclasts (Figure 3D). It therefore appears that the impaired
osteoclastogenesis of ASXL2/ BMMs reflects failed activa-
tion of the RANKL canonical signaling pathway. In fact,
RANKL-stimulated cytoplasmic and nuclear osteoclastogenic
signals are compromised in ASXL2/ cells (Figures 3E and
3F). Furthermore, RANK expression by BMMs and pre-fusion
osteoclasts is diminished in the absence of ASXL2 (Figure 3G).
These observations suggest that normal expression of RANK,
when activated, is necessary and may be sufficient to mediate
ASXL2-stimulated osteoclast formation. Such being the case,
activated RANK should rescue the ASXL2/ osteoclast pheno-
type. To confirm this notion, we expressed a protein consisting
of the transmembrane and cytosolic domains of RANK fused
to the external domain of human Fas receptor (hFas/RANK)
(Izawa et al., 2012). When exposed to anti-hFas antibody, WT
macrophages bearing this construct differentiate into osteo-
clasts (Figure 3H). ASXL2/ BMMs, however, fail to do so.
This observation is in keeping with the failure of RANKL abun-
dance to influence differentiation of ASXL2/ osteoclast
Figure 2. ASXL2 Mediates PPARg-Stimulated Osteoclastogenesis
(A) PPARg and/or ASXL2 were transfected into 293T cells containing a PPARg luciferase reporter construct. The cells were treated with ROSI or carrier and
luciferase activity determined.
(B) 293T cells, transfected with HA-ASXL2 and PPARg, were exposed to ROSI or carrier. HA immunoprecipitates were immunoblotted for PPARg.
(C) BMMs were cultured in the presence of M-CSF and RANKL with or without ROSI. After 5 days, CD36 mRNA was determined by qPCR.
(D) 293Tcells transfectedwithvariouscombinationsofRFP-SUMO1,FLAG-PPARg, andASXL2.FLAG immunoprecipitateswere immunoblotted forFLAGandRFP.
(E) BMMs were exposed to M-CSF and RANKL ± ROSI. After 5 days, osteoclast differentiation markers were determined by qPCR.
(F) BMMs were exposed to M-CSF and RANKL with time. c-Fos protein was measured.
(G andH) ASXL2/BMMs, transduced with c-Fos or vector, were exposed toM-CSF and RANKL and (G) stained for TRAP activity. (H) Expression of osteoclast
differentiation proteins was determined by immunoblot.
(I) BMMs were exposed to M-CSF and RANKL for 3 days with ROSI or carrier. PPARg binding to its response element in the c-Fos promoter was determined by
ChIP assay. The scale bar represents 400 mm.
Data are expressed as mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001.precursors (Figures 1E and S1D). Thus, even in the presence of
activated RANK, ASXL2 is necessary for the osteoclastogenic
process.
c-Fos expression is central to the means by which activated
RANK promotes osteoclast formation. Because ASXL2 is also
required for c-Fos expression, we asked whether the inability
of hFas/RANK to rescue themutant cells reflects failure to induce
the AP-1 transcription factor, and we find such to be the case
(Figure 3I). Thus, the osteoclastogenic properties of RANK
require ASXL2, which is essential for expression of the RANKL
receptor, as well as c-Fos.CeASXL2 Promotes PGC-1b Expression and
Osteoclastogenic Activity
Like PPARg, its co-activator, PGC-1b, is essential for osteoclas-
togenesis, in vitro (Ishii et al., 2009). Given the functional relation-
ship between PPARg and PGC-1b, we asked whether the latter
participates in ASXL2’s osteoclastogenic properties. Unlike the
stable expression of ASXL2 (Figure S2C), PGC-1b progressively
increases during osteoclastogenesis in an ASXL2-dependent
manner (Figures 4A and 4B). In fact, absence of ASXL2 obviates
both basal and ROSI-stimulated PGC-1b expression during
osteoclast differentiation (Figures 4A–4C). Furthermore, ASXL2ll Reports 11, 1625–1637, June 16, 2015 ª2015 The Authors 1629
Figure 3. RANK-Stimulated Osteoclast For-
mation Requires ASXL2
(A–C) ASXL2/ BMMs, transduced with NFATc1
or vector, were exposed to M-CSF and RANKL for
5 days. WT BMMs transduced with vector served
as control. The cells were (A) stained for TRAP, (B)
osteoclasts counted, and (C) osteoclastogenic
proteins were determined.
(D) ASXL2/ BMMs, transduced with NFATc1
or vector, were exposed to M-CSF and RANKL
for 1 day. NFATc1 and c-Fos expression was
determined.
(E and F) Cytokine/serum-starved BMMs were
exposed to RANKL with time. (E) Cytoplasmic
osteoclastogenic signaling molecule activation
and (F) nuclear osteoclastogenic signaling mole-
cule activation were determined by immunoblot.
(G) BMMs were maintained in M-CSF alone for
3 days (0) or M-CSF and RANKL for 48 or 72 hr.
RANK protein was measured.
(H) BMMs, transduced with hFas/RANK, were
exposed to M-CSF and anti-Fas-activating anti-
body for 5 days. The cells were stained for TRAP
activity.
(I) c-Fos expression byWT and ASXL2/BMMs,
transduced with hFas/RANK or vector and
exposed to M-CSF and anti-Fas-activating anti-
body, was determined. The scale bar represents
400 mm.
Data are expressed as mean ± SD; **p < 0.01.localizes with PGC-1b on the retinoic acid response element, a
process mediated by PPARg activation as evidenced by the
stimulatory effect of ROSI (Figure 4D).
PGC-1b is proposed to impact the osteoclast by two distinct
yet integrated pathways. First, by activating PPARg, PGC-1b is
believed to participate in c-Fos induction (Wei et al., 2010). Sec-
ond, PGC-1b, when reciprocally induced by activated PPARg,
promotes mitochondrial biogenesis, considered necessary for
osteoclast differentiation and/or function (Ishii et al., 2009; Wei
et al., 2010). To determine whether ASXL2 regulates generation
of osteoclast mitochondria, we treated mutant and WT BMMs
with various combinations of RANKL ± ROSI. Mitochondrial
enzymemRNA abundancewas determined after 3 days. Consis-
tent with the copious mitochondria characterizing mature osteo-
clasts, basal- and ROSI- induced enzyme mRNA expression is
blunted in cells lacking ASXL2 (Figure 4E). Thus, ASXL2 is neces-
sary for normal mitochondrial biogenesis, which is augmented
by activated PPARg.
Given its central role in osteoclast mitochondrial biogenesis,
we next asked whether PGC-1b mediates ASXL2’s effects on
the process. Thus, we transduced ASXL2/ BMMs with
PGC-1b and exposed them to M-CSF ± RANKL. PGC-1b
completely normalizes mitochondrial enzyme expression by
ASXL2/ osteoclast lineage cells (Figure 4F). Surprisingly,
however, PGC-1b does not rescue the failure of ASXL2-defi-
cient BMMs to commit to the osteoclast phenotype and is
actually suppressive, as evidenced by decreased cathepsin1630 Cell Reports 11, 1625–1637, June 16, 2015 ª2015 The AuthorsK (Figure 4G). This observation raised the possibility that
PGC-1b does not induce essential osteoclastogenic transcrip-
tion factors such as c-Fos. To determine whether this is so, we
transduced ASXL2/ BMMs with c-Fos or PGC-1b. Vector-
bearing ASXL2/ cells served as control. The cells were
cultured for 24 hr in M-CSF, with or without RANKL. Despite
robust expression of transduced c-Fos and PGC-1b, each fails
to enhance mRNA of the other in ASXL2/ BMMs or pre-
fusion osteoclasts (pOCs) (Figure 4H). In fact, PGC-1b actually
diminishes c-Fos mRNA abundance. Furthermore, whereas
PGC-1b rescues expression of the five principal eukaryotic
mitochondrial enzyme complexes (OXPHOS proteins) in
ASXL2/ BMMs and/or pOCs, c-Fos has no such effect (Fig-
ure 4I). Hence, PGC-1b and mitochondrial biogenesis,
together, are insufficient to promote ASXL2/ osteoclast for-
mation as they do not induce c-Fos or the osteoclast-specific
protein, cathepsin K. Similarly, c-Fos fails to induce PGC-1b
expression or mitochondrial biogenesis. These observations
suggest ASXL2 regulates two distinct pathways in osteoclasts.
The first involves PGC-1b-stimulated energy metabolism,
which mediates the mature cell’s capacity to degrade bone,
whereas the second involves c-Fos promotion of osteoclast
differentiation.
ASXL2 Does Not Suppress Key PPARg Co-repressors
These data indicate ASXL2 likely promotes osteoclastogene-
sis in association with transactivation of PGC-1b, a PPARg
Figure 4. ASXL2 Promotes PGC-1b Expression
(A) BMMs were maintained in M-CSF and RANKL. PGC-1b was temporally measured by immunoblot.
(B and C) BMMs were maintained in M-CSF and RANKL ± ROSI or carrier. PGC-1b (B) mRNA and (C) protein were measured by qPCR and immunoblot,
respectively.
(D and E) BMMs were maintained in M-CSF and RANKL ± ROSI or carrier for 3 days. (D) ASXL2 binding to the retinoic acid response element in the PGC-1b
promoter was determined by ChIP assay. (E) Mitochondrial enzyme mRNAs were measured by qPCR.
(F and G) ASXL2/ BMMs, transduced with PGC-1b or vector, were maintained in M-CSF without (MF) or with RANKL (pOC) for 3 days. (F) Mitochondrial
enzyme (Cox3) and (G) cathepsin K mRNA were measured by qPCR. Vector-bearing WT cells serve as control.
(H) ASXL2/ BMMs transduced with PGC-1b, c-Fos, or vector were maintained in M-CSF without (MF) or with RANKL (pOC) for 3 days. c-Fos and PGC-1b
mRNAs were determined by qPCR. Vector-bearing ASXL2/ BMMs serve as control.
(I) Immunoblot of mitochondrial respiratory chain subunits (complexes I–V) expressed by BMMs and pOC derived fromWT and ASXL2/mice transduced with
vector, c-Fos, or PGC-1b.
Data are expressed as mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001.co-activator. However, they do not exclude the possibility that
ASXL2 also exerts its osteoclastogenic effects by suppressing
transcription of a PPARg co-repressor(s). This hypothesis is in
keeping with the fact that ASXL2 is an ETP protein that regu-
lates histone 3 methylation to establish repressive or active
chromatin configurations at target loci (Baskind et al., 2009).
Indicating ASXL2 does not suppress PPARg co-repressors,
the mRNA abundance of two such key inhibitors, NCoR and
SMRT, does not increase in the absence of the ETP proteinCe(Yu et al., 2005) (Figure S3). Thus, the osteoclastogenic prop-
erties of ASXL2 are mediated by activating PPARg and prob-
ably not by inhibiting its repression.
ASXL2 Deficiency Promotes Insulin Resistance and
Glucose Intolerance
PPARg plays a central role in insulin sensitivity. Because
ASXL2 activates PPARg in the osteoclastogenic process, we
postulated ASXL2 may also promote glucose homeostasis.ll Reports 11, 1625–1637, June 16, 2015 ª2015 The Authors 1631
Figure 5. ASXL2 Regulates Glucose and
Insulin Sensitivity
(A) Glucose tolerance test and its area under the
curve of WT and ASXL2/ mice.
(B) Insulin tolerance test and its area under the
curve of WT and ASXL2/ mice.
(C and D) WT and ASXL2/ mice were injected
with insulin (5 U/kg) or PBS. Ten minutes later,
phosphorylation of Akt and the insulin receptor
was determined by immunoblot in (C) liver and (D)
gastrocnemius muscle.
(E) Glucose-6-phosphatase (G-6-Pase) and phos-
phoenolpyruvate carboxykinase (Pepck) mRNA
wasmeasuredbyqPCR inWTandASXL2/ liver.
(F) CD36 mRNA expression by liver, muscle, and
epididymal white adipose tissue (eWAT) as
determined by qPCR.
(G) Irradiated WT mice were transplanted with WT
or ASXL2/ marrow. Six weeks later, the ani-
mals were subjected to glucose tolerance tests.
(H–J) WT and ASXL2/ BMMs were exposed to
insulin. Phosphorylated (H) AKT, (I) insulin recep-
tor, and (J) S6 were determined by immunoblot.
Data are expressed as mean ± SD; *p < 0.05; **p <
0.01; ***p < 0.001.In fact, ASXL2/ mice are glucose intolerant (Figure 5A).
Consistent with this condition, basal serum glucose is
increased in fasting and fed states (Fast-WT 65.4 ± 11.4;
ASXL2/ 112.6 ± 18.4; Fed-WT 118.7 ± 15.26; ASXL2/
170.75 ± 31.82; mg/dl ± SD; p < 0.01). On the other hand
and typical of early onset T2-DM, their circulating basal insulin
is normal (WT 0.31 ± 0.10; ASXL2/ 0.32 ± 0.17; ng/ml ±
SD). Asxl2-deficient mice also exhibit attenuated clearance
of glucose following insulin challenge (Figure 5B). Insulin resis-
tance in ASXL2-deficient mice is further substantiated by the
inability of liver and muscle to phosphorylate Akt or the insulin
receptor in response to in vivo insulin administration (Figures
5C and 5D). The mice also exhibit increased hepatic expres-
sion of the gluconeogenic enzymes, glucose-6-phosphatase
and phosphoenolpyruvate carboxykinase (Figure 5E). The
role of PPARg in ASXL2/ extraskeletal insulin resistance
is supported by suppressed expression of CD36 in mutant
liver, fat, and muscle (Figure 5F) (Hu et al., 2012). Thus,
ASXL2 deficiency produces a state of insulin-resistant
glucose intolerance in conjunction with failed osteoclastogen-
esis and osteopetrosis.
ASXL2 Does Not Regulate Glucose Metabolism via Its
Expression in Osteoclasts
Osteoclasts may participate in the pathogenesis of murine
diabetes (Ferron et al., 2010). To determine whether ASXL2
deficiency in the bone-resorptive cell modifies glucose homeo-1632 Cell Reports 11, 1625–1637, June 16, 2015 ª2015 The Authorsstasis, we transplanted WT or ASXL2/
marrow into irradiated WT mice (Lam
et al., 2000). Despite the fact that
transplantation of the mutant marrow
into irradiated WT mice yields theASXL2/ osteoclast phenotype (Figure 1F), glucose tolerance
remains normal as it mirrors that of WT to WT transplantation
(Figure 5G). Thus, in contrast to murine T1-DM, in which osteo-
clast dysfunction might be pathogenic (Ferron et al., 2010), the
resorptive cell’s abnormalities do not appear to contribute to
systemic insulin resistance in ASXL2 deficiency.
ASXL2-Mediated Insulin Sensitivity Does Not Regulate
Osteoclastogenesis
ASXL2/ BMMs are also insulin resistant, as evidenced by
diminished InR, Akt, and S6(S235/236) phosphorylation in
response to the hormone (Figures 5H–5J). As BMMs are
osteoclast precursors, this observation suggests their insulin
insensitivity may contribute to the attenuated osteoclastogene-
sis attending ASXL2 deficiency. To determine whether insulin
signaling in osteoclast precursors is necessary for the osteo-
clastogenic process, we deleted the InR in InRfl/fl BMMs,
with retroviral Turbo-cre (Bai et al., 2008). As seen in Figures
S4A and S4B, absence of the InR does not alter differentiation
of osteoclast precursors. Thus, failure of ASXL2-deficient oste-
oclast formation does not reflect insulin insensitivity of
precursors.
ASXL2/ Mice Are Lipodystrophic
PPARg is required for adipogenesis, and its absence produces a
lipodystrophic state. Similarly, ASXL2 overexpression in 3T3-L1
pre-adipocytes transactivates adipogenic genes (Park et al.,
Figure 6. ASXL2/ Mice Are Lipody-
strophic.
(A) Weight of BAT, eWAT, and scWAT in WT and
ASLX2/ mice.
(B) Fat/lean ratio of WT and ASXL/ mice.
(C) WT and ASXL2/ mice were injected
with insulin (5 U/kg) or PBS. Ten minutes later,
phosphorylation of Akt in epididymal fat was
determined by immunoblot.
(D) WT and ASXL2/ adipocyte size measured
by osmium tetroxide staining.
(E) Adipocyte number in WT and ASXL2/
epididymal fat pad.
(F) mRNA of adipogenic genes in ASXL2/ and
WT eWAT was measured by qPCR.
(G) Marrow stromal cells of WT and ASXL2/
mice were cultured in adipogenic conditions for
14 days. The cells were stained with oil red O (red
reaction product) to identify lipid.
(H) eWAT was treated with DMSO or isoproterenol
for 1 hr. Media glycerol content was determined.
(I) mRNA of lipid storage genes in WT and
ASXL2/ eWAT was measured by qPCR.
(J) Serum triglycerides and cholesterol of chow-
fed WT and ASXL2/ mice. The scale bar rep-
resents 50 mm.
Data are expressed as mean ± SD; *p < 0.05;
***p < 0.001.2011). In consequence, ASXL2/ mice are partially lipody-
strophic, as manifested by decreased abundance of epididymal
(eWAT) and subcutaneous (scWAT) white and brown (BAT) adi-
pose tissue as well as DXA-determined fat/lean ratio (Figures
6A, 6B, S5A, and S5B). Despite the paucity of fat, VO2 is only
slightly decreased and exclusively in light cycle (Figure S5C).
Likewise, respiratory quotient (RQ) of ASXL2/ mice mirrors
that of WT. These data suggest ASXL2/ and WT mice enjoy
similar use of fuels as energy source.
ASXL2/ adipocytes are insulin insensitive, as they fail to
optimally phosphorylate Akt308 in response to the hormone (Fig-
ure 6C). Mirroring cells in which PPARg is inactive, ASXL2-defi-
cient adipocytes are small and their abundance is diminished
(Figures 6D, 6E, S5D, and S5E). Histological analysis of BAT
and expression of the thermogenic marker, UCP1, remains un-
changed in eWAT and BAT, suggesting beiging of WAT doesCell Reports 11, 1625–163not induce the small adipocytes of
ASXL2 deficiency (Figures S5F and
S5G). Unlike cells in muscle and liver,
ASXL2/ adipocytes normally phos-
phorylate their InR (Figure S5H). On the
other hand, expression of adiponectin
and leptin by adipocyte is reduced,
attesting to insulin insensitivity and the
lipodystrophic phenotype (Figure 6F).
Confirming compromised adipogenic
capacity, differentiation of ASXL2/
marrow stromal cells into fat is arrested
(Figure 6G). Similarly, shRNA knockdown
of ASXL2 reduces lipid accumulation inNIH 3T3-L1 cells, corroborating the cell-autonomous nature of
the process (Figure S5I). Additionally, C/EBPa mRNA, whose
product regulates leptin and PPARg expression and promotes
osteoclast formation (Chen et al., 2013), is reduced in
ASXL2/ fat (Figure 6F). The same holds regarding mRNA for
AP2, CD36 (both induced by PPARg), and solute carrier family
25, member 1 (slc25a1). In contrast to these proteins, which
promote maturation of differentiating adipocytes, expression of
C/EBPb, which stimulates earlier, pre-adipocyte maturation, is
increased.
ASXL2 deletion does not affect glycerol mobilization even in
presence of isoproterenol induction, indicating that the atten-
dant paucity of fat is not due to enhanced lipolysis (Figure 6H).
On the other hand, proteins, which mediate lipid storage,
including fatty acid synthase (Fasn), acetyl-CoA carboxylase 1
(Acaca), malic enzyme 1 (Me1), and Glut 4, are diminished in7, June 16, 2015 ª2015 The Authors 1633
Figure 7. ASXL2-Deficient Mice Resist
High-Fat Diet
WT and ASXL2/mice were maintained on HFD
for 7 weeks.
(A) Body weight.
(B) Weekly food intake.
(C) Fat/lean ratio as determined by DXA.
(D) Glucose tolerance test.
(E) Insulin tolerance test.
(F) Adiponectin and leptin content in eWAT.
Data are expressed as mean ± SD; **p < 0.01;
***p < 0.001.ASXL2/ WAT (Figure 6I). In keeping with failure to store
lipids, circulating triglycerides and cholesterol are increased
in ASXL2-deficient mice (Figure 6J). Despite compromised lipid
storage, liver and muscle fat are not enhanced in the mutant
mice (Figures S5J–S5L). Thus, the lipodystrophic state of
ASXL2/ mice likely reflects defective lipid storage and not
enhanced lipolysis.
ASXL2-Deficient Mice Resist HFD
Obesity promotes insulin resistance, suggesting that compro-
mised adipogenesis may be protective in this regard. To deter-
mine whether such is the case, we fed WT and ASXL2/
mice a HFD for 7 weeks. As expected WT mice gain substantial
weight. In contrast, ASXL2-deficient animals fail to increase
body mass despite similar food consumption (Figures 7A and
7B). Hence, the fat/lean ratio, as determined by DXA, remains
low in HFD-fed ASXL2/ mice (Figure 7C). Whereas there is
no discernable difference in marrow adipose tissue in chow-
fed animals, there is substantially less in the pair of femurs
obtained from ASXL2/ HFD mice (Table S1).
As expected, the metabolic phenotype is exacerbated in WT
animals by HFD (Figures 7D–7F). Chow-fed ASXL2/ mice1634 Cell Reports 11, 1625–1637, June 16, 2015 ª2015 The Authorsare insulin resistant based on glucose-
and insulin-tolerance tests, but this
condition is not exacerbated by HFD. Lip-
okine levels reflect the expected physi-
ology in WT mice with increases in leptin
and decreases in adiponectin (Figure 7F),
but these changes are substantially
blunted in ASXL2/ mice. This robust
difference is consistent with the complex
lipodystrophic phenotype of these mice
and highlights the critical role of ASXL2
in the integrative physiology of lipid,
glucose, and skeletal metabolism.
DISCUSSION
Our exploration of ASXL2 was prompted
by its association with BMD in mice and
man (Farber et al., 2011; Ghazalpour
et al., 2012; Nielson et al., 2010). Because
ASXL2 expression is linked to genes
regulating myeloid differentiation, wesuspected its skeletal effects are mediated via the osteoclast.
In fact, both knockdown of ASXL2 and its absence in osteoclast
precursors markedly arrest the osteoclastogenic process. Mir-
roring these in vitro experiments, the number of osteoclasts in
ASXL2/ mice is substantially reduced and ASXL2/ mice
are osteopetrotic. These animals also manifest systemic insulin
resistance. These observations suggest that ASXL2 may partic-
ipate in the complex relationship between skeletal biology and
metabolism manifest in obesity-related diabetes.
Osteoclast formation may be regulated in a cell-autonomous
(i.e., endogenous to the osteoclast) or non-autonomous manner.
Non-autonomous osteoclastogenesis typically involves altered
secretion of the key osteoclastogenic cytokines, RANKL and
M-CSF, by non-osteoclastic cells such as those ofmesenchymal
or T cell lineage. Despite compromised RANKL expression by
mutant osteoblasts, our observation that pure populations of
ASXL2/ BMMs fail to normally differentiate into osteoclasts
indicated ASXL2’s effects are principally cell autonomous. On
the other hand, the magnitude of priming BMMs by RANKL,
in vivo, may affect their subsequent capacity to commit to the
osteoclast phenotype (Lam et al., 2000). The fact that the WT
construct substantially rescues ASXL2/ osteoclastogenesis
that, in turn, is induced by transplantation of mutant marrow into
irradiated WT mice substantiates ASXL2’s osteoclast autono-
mous nature.
Our conjecture that the osteoclastogenic effects of PPARg
require ASXL2was prompted by the observation that the two nu-
clear proteins interact (Park et al., 2011). The essential role
ASXL2 plays in PPARg-induced osteoclast formation is estab-
lished by ASXL2 being necessary for basal and TZD-stimulated
activation of a PPARg reporter construct. ASXL2 also promotes
binding of PPARg to its c-Fos response element and, most
importantly, is essential for expression of c-Fos and NFATc1.
These observations indicate that the attenuated osteoclastogen-
esis attending ASXL2 deficiency reflects failure to express these
TZD-induced transcription factors. Establishing this case, trans-
duction of c-Fos or NFATc1 in ASXL2/ BMMs promotes their
differentiation into osteoclasts.
Osteoblasts and adipocytes have a common mesenchymal
precursor, and therefore, their differentiation is competitive
(Wan, 2010). PPARg plays a central role in this selection as
its activation promotes adipogenesis at the cost of the osteo-
blast. Based on the abundance of ASXL2 in osteoblasts, we
expected its deficiency would enhance bone formation,
contributing to the marked increase in trabecular bone volume.
By this scenario, ASXL2 deficiency would obviate the pro-adi-
pogenic effects of PPARg, thereby encouraging osteoblast dif-
ferentiation of their common precursor. Our in vitro and in vivo
data establish such is not the case, as multiple parameters
of bone formation, including osteocalcin, are unaltered in
ASXL2/ mice. Interestingly, the metabolic characteristics
of ASXL2/ mice, which have normal circulating osteocalcin
and insulin, differ from those deficient in the osteoblast-spe-
cific protein. For example, lack of osteocalcin promotes
obesity (Lee et al., 2007). In contrast, fat mass and adipocyte
differentiation of ASXL2/ mice are diminished, likely reflect-
ing relatively late arrest of the adipogenic process and lipid
storage. Thus, regulation of glucose homeostasis by osteocal-
cin and ASXL2 mechanistically differ. Whereas decreased os-
teocalcin principally compromises insulin production, absence
of ASXL2 results in insulin resistance. Furthermore, despite
evidence indicating the osteoclast participates in osteocal-
cin-mediated glucose homeostasis (Ferron et al., 2010), WT
marrow transplanted into ASXL2/ mice fails to rescue their
diabetic state. Thus, whereas bone and glucose metabolism
are each mediated by PPARg, the effects of ASXL2 on the
two events appear to be physiologically distinct. Our demon-
stration that, unlike ROSI, a TZD with impaired recognition of
PPARg (Chen et al., 2012) fails to promote osteoclast forma-
tion provides credence to the concept that insulin sensitivity
of BMMs does not impact their osteoclastogenic potential
(Fukunaga et al., 2015).
The activity of PPARg is dictated by ligand-induced disassoci-
ation of co-repressors and recruitment of co-stimulatory mole-
cules. The varied distribution of PPARg co-activators likely
dictates tissue specificity of the nuclear receptor’s transcrip-
tional effects (Ahmadian et al., 2013). PGC-1b is believed to be
a prevalent PPARg co-activator in the osteoclastogenic process.
Its expression is enhanced during osteoclast differentiation, and
its deletion arrests formation of the bone-resorptive cell, in vitro,Ceparticularly when induced by ROSI (Ishii et al., 2009; Wei et al.,
2010). Because ASXL2 exerts its osteoclastogenic effects in
conjunction with PPARg, we asked whether PGC-1b partici-
pates in the process. Mirroring the effects of PPARg deletion,
absence of ASXL2 completely obviates PGC-1b expression
both basally and when induced by ROSI.
Dysfunctional mitochondrial biogenesis is central to the path-
ogenesis of insulin-resistant DM (Petersen et al., 2003; Vianna
et al., 2006). This mitochondrial dysfunction is mediated by
PGC-1a and its closest homolog, PGC-1b.Whereas overexpres-
sion of either increases mitochondrial respiration in cultured
cells, they are non-compensatory, as deletion of either promotes
a robust phenotype and selectively alters gene expression (Lin
et al., 2004; Sonoda et al., 2007). This event is of particular sig-
nificance in osteoclasts that, because of profound energy con-
sumption, are extremely rich in mitochondria whose generation
requires PGC-1b. In fact, absence of PGC-1b arrests the bone-
resorptive function of mature osteoclasts, in vivo (Ishii et al.,
2009). However, the relative importance of PGC-1b and its in-
duction of mitochondrial biogenesis to osteoclast formation
were unknown.
Similar to PGC-1b, absence of ASXL2 diminishes basal and
stimulated mitochondrial biogenesis. However, unlike c-Fos or
NFATc1, which rescue the ASXL2/ osteoclast phenotype,
reconstitution with PGC-1b has no effect on differentiation of
the mutant cells. These observations are consistent with the
fact that, whereas PGC-1b/ osteoclast number is diminished,
in vitro, it is normal, in vivo, but function of the cell is disturbed
(Ishii et al., 2009). In a physiological context, therefore, PGC-1b
and by association mitochondrial biogenesis likely exert their ef-
fects by enabling resorptive activity and not by promoting oste-
oclast differentiation.
Arrest of differentiation-induced expression of RANK and its
effector osteoclastogenic signals provided a candidate mecha-
nism for failure to optimally form the bone-resorbing cells in
the absence of ASXL2. Thus, it was surprising that normalization
of RANK does not increase c-Fos, which when transduced into
ASXL2/ BMMs, rescues their osteoclast-poor phenotype.
PGC-1b transduction, which promotes mitochondrial biogen-
esis, also fails to induce c-Fos or osteoclast formation in
ASXL2/ cells. Thus, regardless of agonist, osteoclastogene-
sis requires c-Fos, which in turn requires ASXL2. We propose
that, in contradistinction to PGC-1b, which via mitochondrial
biogenesis directly facilitates bone resorption, the primary oste-
oclastic effect of c-Fos, which does not enhance PGC-1b
expression or mitochondrial biogenesis, is maturation, with
increased bone degradation being a secondary consequence.
Thus, ASXL2 regulates osteoclast formation and function,
respectively, by two distinct signaling pathways.
The role of ASXL2 in skeletal, glucose, and lipid homeostasis
establishes that this particular gene regulates all three systems.
On the other hand, the products of ASXL2-mediated regulation,
such as osteoclastogenesis and insulin sensitivity, appear to be
independent events that do not mutually impact each other.
Thus, murine ASXL2 insufficiency predisposes to lipodystrophy,
insulin resistance, and attendant skeletal dysfunction, raising
the possibility that ASXL2 may affect similar endpoints in
people.ll Reports 11, 1625–1637, June 16, 2015 ª2015 The Authors 1635
EXPERIMENTAL PROCEDURES
Detailed information is available in the Supplemental Experimental
Procedures.
Mice
ASXL2+/ mice (C57BL background and S129 background) were described
previously (Baskind et al., 2009). To generate ASXL2/ mice, C57BL
ASXL2+/ mice were mated with S129 ASXL2+/ mice; F1 offspring were
used for all experiments. Mice were housed in the animal care unit of Washing-
ton University School of Medicine, where they were maintained according to
guidelines of the Association for Assessment and Accreditation of Laboratory
Animal Care. All animal experimentation was approved by the Animal Studies
Committee of Washington University School of Medicine.
Statistics
Statistical significance was determined using Student’s t test. Data are
expressed as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 in all
experiments.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.05.019.
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